Company Kyongbo Pharmaceutical Co., Ltd

Company Kyongbo Pharmaceutical Co., Ltd

A214390

KR7214390007

Pharmaceuticals

Equities

A214390

KR7214390007

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 19:00:00 2024-03-26 EDT			5-day change	1st Jan Change
7,440 ^KRW	-2.75%		-.--%	-11.32%

2023	Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd	CI
2023	Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

KYONGBO PHARMACEUTICAL CO., LTD is a Korea-based company principally engaged in manufacturing and distributing pharmaceutical products The Company operates its business through two segments: raw material medicine segment, which produces atorvastatin, ceftizoxime, ceftriaxone, clarithromycin and Pranlukast, and medicine segment, which produces surgeon respiratory solution, cefaclor capsule and cefaclor dry syrup. The Company distributes its products within domestic market and to overseas markets including China Japan and Europe.

KRW in Million	2022	Weight	2023	Weight	Delta
Raw Material 64.7 %	144,076	73.4 %	139,990	64.7 %	-2.84%
Finished Product 35.3 %	52,189	26.6 %	76,368	35.3 %	+46.33%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 75.4 %	132,906	67.7 %	163,116	75.4 %	+22.73%
Asia 22.5 %	58,631	29.9 %	48,717	22.5 %	-16.91%
Europe 1.8 %	4,409	2.2 %	3,874	1.8 %	-12.13%
Other 0.3 %	319	0.2 %	650	0.3 %	+103.87%

Managers	Title	Age	Since
Tae-Young Kim CEO	Chief Executive Officer	65	-
Byung-Ok Kim CTO	Chief Tech/Sci/R&D Officer	53	-
Jae-Taek Hwang CTO	Chief Tech/Sci/R&D Officer	60	-
Saeng-Gyu Seo BRD	Director/Board Member	65	-
Kyung-Soo Kim SAM	Sales & Marketing	57	-
Chun-Bong Lee SAM	Sales & Marketing	62	-
Do-Kyung Kim AUD	Comptroller/Controller/Auditor	56	-
Kyu-Jae Lee SAM	Sales & Marketing	57	-
Jang-Han Lee PRN	Corporate Officer/Principal	71	-

Members of the board	Title	Age	Since
Tae-Young Kim CEO	Chief Executive Officer	65	-
Saeng-Gyu Seo BRD	Director/Board Member	65	-
Jae-Taek Hwang CTO	Chief Tech/Sci/R&D Officer	60	-
Woo-In Lee BRD	Director/Board Member	53	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	23,906,860	9,109,660 ( 38.10 %)	0	38.10 %

Name	Equities	%	Valuation
CHONG KUN DANG HOLDINGS CORP. 43.41 %	10,377,045	43.41 %	57 M ₩
Joo-won Rhee 4.715 %	1,127,280	4.715 %	6 M ₩
Joo-gyung Rhee 4.364 %	1,043,280	4.364 %	6 M ₩
Joo-ah Rhee 4.007 %	957,972	4.007 %	5 M ₩
Jang-Han Lee 2.005 %	479,363	2.005 %	3 M ₩
Jae-jung Chung 2.000 %	478,140	2.000 %	3 M ₩
Kyongbo Pharmaceutical Co. Ltd. Esoa 1.557 %	372,344	1.557 %	2 M ₩
Dimensional Fund Advisors Ltd. 0.0139 %	3,322	0.0139 %	18 325 ₩
DFA Australia Ltd. 0.001288 %	308	0.001288 %	1 699 ₩

Name	Equities	%	Valuation
MYUNGMOON PHARM CO.,LTD 4.21%	1,429,642	4.21%	2,161,890 $

KYONGBO PHARMACEUTICAL Co., Ltd.

174 Sirok-ro

31501, Asan-si

http://www.kbpharma.co.kr

address Kyongbo Pharmaceutical Co., Ltd(A214390)

	1st Jan change	Capi.
KYONGBO PHARMACEUTICAL CO., LTD	-11.32%	131M
ELI LILLY AND COMPANY	+38.35%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.70%	364B
MERCK & CO., INC.	+20.08%	332B
ABBVIE INC.	+5.01%	291B
ASTRAZENECA PLC	+17.16%	238B
ROCHE HOLDING AG	-3.76%	210B
NOVARTIS AG	+10.46%	209B
AMGEN INC.	+8.55%	169B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals